These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 33329552)

  • 1. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity.
    Yasinska IM; Meyer NH; Schlichtner S; Hussain R; Siligardi G; Casely-Hayford M; Fiedler W; Wellbrock J; Desmet C; Calzolai L; Varani L; Berger SM; Raap U; Gibbs BF; Fasler-Kan E; Sumbayev VV
    Front Immunol; 2020; 11():580557. PubMed ID: 33329552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Tim-3-galectin-9 Secretory Pathway is Involved in the Immune Escape of Human Acute Myeloid Leukemia Cells.
    Gonçalves Silva I; Yasinska IM; Sakhnevych SS; Fiedler W; Wellbrock J; Bardelli M; Varani L; Hussain R; Siligardi G; Ceccone G; Berger SM; Ushkaryov YA; Gibbs BF; Fasler-Kan E; Sumbayev VV
    EBioMedicine; 2017 Aug; 22():44-57. PubMed ID: 28750861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional role of galectin-9 in directing human innate immune reactions to Gram-negative bacteria and T cell apoptosis.
    Schlichtner S; Meyer NH; Yasinska IM; Aliu N; Berger SM; Gibbs BF; Fasler-Kan E; Sumbayev VV
    Int Immunopharmacol; 2021 Nov; 100():108155. PubMed ID: 34543981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins.
    Schlichtner S; Yasinska IM; Lall GS; Berger SM; Ruggiero S; Cholewa D; Aliu N; Gibbs BF; Fasler-Kan E; Sumbayev VV
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36599470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Tim-3-Galectin-9 Pathway and Its Regulatory Mechanisms in Human Breast Cancer.
    Yasinska IM; Sakhnevych SS; Pavlova L; Teo Hansen Selnø A; Teuscher Abeleira AM; Benlaouer O; Gonçalves Silva I; Mosimann M; Varani L; Bardelli M; Hussain R; Siligardi G; Cholewa D; Berger SM; Gibbs BF; Ushkaryov YA; Fasler-Kan E; Klenova E; Sumbayev VV
    Front Immunol; 2019; 10():1594. PubMed ID: 31354733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectins and their ligands: negative regulators of anti-tumor immunity.
    Cedeno-Laurent F; Dimitroff CJ
    Glycoconj J; 2012 Dec; 29(8-9):619-25. PubMed ID: 22544342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of Tumor-Specific Cytotoxic T Lymphocytes in Acute Myeloid Leukemia Patients Through the Identification of T-Cells Capable to Establish Stable Interactions With the Leukemic Cells: "Doublet Technology".
    García-Guerrero E; Sánchez-Abarca LI; Domingo E; Ramos TL; Bejarano-García JA; Gonzalez-Campos JA; Caballero-Velázquez T; Pérez-Simón JA
    Front Immunol; 2018; 9():1971. PubMed ID: 30233577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-9 and VISTA Expression Define Terminally Exhausted T Cells in HIV-1 Infection.
    Shahbaz S; Dunsmore G; Koleva P; Xu L; Houston S; Elahi S
    J Immunol; 2020 May; 204(9):2474-2491. PubMed ID: 32205423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse CD8
    Li Z; Wu Y; Wang C; Zhang M
    Cancer Immunol Immunother; 2019 Aug; 68(8):1303-1315. PubMed ID: 31278476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectins as regulators of cell survival in the leukemia niche.
    Ruvolo PP
    Adv Biol Regul; 2019 Jan; 71():41-54. PubMed ID: 30245264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
    Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VISTA expression and patient selection for immune-based anticancer therapy.
    Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
    Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C; Mukhopadhyay S; Kovacs E; Medina R; Patel P; Catina TL; Campbell KS; Santoli D
    J Leukoc Biol; 2005 Aug; 78(2):359-71. PubMed ID: 15937142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate Immunity Protein Tag7 Induces 3 Distinct Populations of Cytotoxic Cells That Use Different Mechanisms to Exhibit Their Antitumor Activity on Human Leukocyte Antigen-Deficient Cancer Cells.
    Sharapova TN; Ivanova OK; Soshnikova NV; Romanova EA; Sashchenko LP; Yashin DV
    J Innate Immun; 2017; 9(6):598-608. PubMed ID: 28977785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transforming growth factor beta type 1 (TGF-β) and hypoxia-inducible factor 1 (HIF-1) transcription complex as master regulators of the immunosuppressive protein galectin-9 expression in human cancer and embryonic cells.
    Selnø ATH; Schlichtner S; Yasinska IM; Sakhnevych SS; Fiedler W; Wellbrock J; Klenova E; Pavlova L; Gibbs BF; Degen M; Schnyder I; Aliu N; Berger SM; Fasler-Kan E; Sumbayev VV
    Aging (Albany NY); 2020 Dec; 12(23):23478-23496. PubMed ID: 33295886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Innate immunity protein Tag7 (PGRP-S) activates lymphocytes capable of Fasl-Fas-dependent contact killing of virus-infected cells.
    Sharapova TN; Ivanova OK; Prasolov VS; Romanova EA; Sashchenko LP; Yashin DV
    IUBMB Life; 2017 Dec; 69(12):971-977. PubMed ID: 29083508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VISTA is an acidic pH-selective ligand for PSGL-1.
    Johnston RJ; Su LJ; Pinckney J; Critton D; Boyer E; Krishnakumar A; Corbett M; Rankin AL; Dibella R; Campbell L; Martin GH; Lemar H; Cayton T; Huang RY; Deng X; Nayeem A; Chen H; Ergel B; Rizzo JM; Yamniuk AP; Dutta S; Ngo J; Shorts AO; Ramakrishnan R; Kozhich A; Holloway J; Fang H; Wang YK; Yang Z; Thiam K; Rakestraw G; Rajpal A; Sheppard P; Quigley M; Bahjat KS; Korman AJ
    Nature; 2019 Oct; 574(7779):565-570. PubMed ID: 31645726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.